Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.
Overview
- Phase
- Not Applicable
- Intervention
- Fluticasone propionate/salmeterol combination
- Conditions
- Asthma
- Sponsor
- GlaxoSmithKline
- Enrollment
- 5180
- Primary Endpoint
- To assess the difference in asthma related exacerbations
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects with asthma as determined by ICD-9 codes and asthma drug use
- •at least 12 years of age
- •treated with inhaled corticosteroids
Exclusion Criteria
- •Subjects with COPD or treatment for COPD
Arms & Interventions
Asthma patients treated with inhaled corticosteroids
Asthma subjects newly prescribed inhaled corticosteriods
Intervention: Fluticasone propionate/salmeterol combination
Asthma patients treated with inhaled corticosteroids
Asthma subjects newly prescribed inhaled corticosteriods
Intervention: Inhaled corticosteroids
Outcomes
Primary Outcomes
To assess the difference in asthma related exacerbations
Time Frame: 90 days post index
Asthma related exaceberation is defined as any asthma related emergency department visit, or inpatient visit or oral corticosteroid dispensing.